2014
Helicobacter pylori Seropositivities and Risk of Pancreatic Carcinoma
Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q, Gao YT, Yu H. Helicobacter pylori Seropositivities and Risk of Pancreatic Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 172-178. PMID: 24234587, PMCID: PMC3947155, DOI: 10.1158/1055-9965.epi-13-0447.Peer-Reviewed Original ResearchConceptsCagA-positive strainsPancreatic cancerPancreatic carcinomaCagA seropositivityPylori seropositivityPylori colonizationGastric acidityH. pyloriLarge population-based case-control studyPopulation-based case-control studyPancreas cancer riskParticular cancer siteVirulence protein CagAHelicobacter pylori seropositivityH. pylori seropositivityBody mass indexH. pylori colonizationCase-control studyHelicobacter pylori colonizationH. pylori CagAStrain typesPathophysiologic actionsVenipuncture specimensAntibody seropositivityCase patients
2000
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer
Farrow D, Vaughan T, Sweeney C, Gammon M, Chow W, Risch H, Stanford J, Hansten P, Mayne S, Schoenberg J, Rotterdam H, Ahsan H, West A, Dubrow R, Fraumeni J, Blot W. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes & Control 2000, 11: 231-238. PMID: 10782657, DOI: 10.1023/a:1008913828105.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseaseNon-cardia gastric adenocarcinomaEsophageal adenocarcinomaGERD symptomsReflux diseaseH2 blockersGastric adenocarcinomaGastric cancerLarge population-based case-control studyPopulation-based case-control studyPopulation-based tumor registryEsophageal squamous cell carcinomaPerson structured interviewRisk of esophagealSquamous cell carcinomaEsophageal adenocarcinoma riskH2-receptor antagonistsCase-control studyGastric cardia adenocarcinomaRandom digit dialingLong-term usersTumor RegistryAdenocarcinoma riskDaily symptomsCell carcinoma